NCT03467945View on ClinicalTrials.gov

Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 16, 2018

Primary Completion Date

April 29, 2018

Study Completion Date

April 29, 2018

Conditions
Healthy
Interventions
DRUG

Metformin/Gliclazide Fixed Combination

Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.

DRUG

Metformin

Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.

DRUG

Gliclazide

Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.

Trial Locations (1)

64293

Please Contact the Merck KGaA Communication Center, Darmstadt

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03467945 - Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants | Biotech Hunter | Biotech Hunter